Inhalation device and drug delivery system

Abstract

The invention relates to the technical field of drug delivery. In particular to an inhalation device and a drug delivery system. The inhalation device includes a mixer, an ultrasonic nebulizer, and a heatable nebulizer. The mixer is provided with a mixing cavity; the ultrasonic atomizer is provided with a first atomization cavity and a first atomization channel communicated with the first atomization cavity, the first atomization channel is communicated with the mixing cavity, and the first atomization cavity is used for containing first liquid; the heatable atomizer is provided with a second atomization cavity and a second atomization channel communicated with the second atomization cavity, the second atomization channel is communicated with the mixing cavity, the second atomization cavity is used for containing second liquid, and the second liquid is a solvent of the first liquid. The inhalation device can improve the solubility of medicine fog drops, control the particle size distribution, adjust the mixing ratio of medicine atomization and a solvent in real time, and reduce the possibility that large fog drop medicine is prone to remaining on the throat and the like.

Description

Technical Field

[0001] The present application relates to the technical field of drug delivery, and in particular to an inhalation device and a drug delivery system. Background Art

[0002] Currently, pulmonary delivery of nanomedicines has attracted considerable attention for the treatment of lung diseases. Lung tissue, due to its unique physiological properties, including a large absorptive surface area, represents a promising drug delivery window. Compared to systemic drug delivery, nanoparticle inhalation offers several advantages for treating lung diseases, including improved pulmonary bioavailability. However, pulmonary delivery of nanomedicines for lung treatment still faces challenges, including low drug droplet solubility, uncontrollable particle size distribution, the inability to adjust the drug atomization and solvent mixing ratio in real time, and the tendency of large droplets to accumulate in the throat.

[0003] The information disclosed in this background section is only intended to enhance understanding of the overall background of the invention and should not be considered as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art. Summary of the Invention

[0004] Based on this, it is necessary to provide an inhalation device and drug delivery system to address the problems of low drug droplet solubility, uncontrollable particle size distribution, inability to adjust the drug atomization and solvent mixing ratio in real time, and large droplet drugs easily remaining in the throat when delivering nanomedicines for lung treatment.

[0005] In a first aspect, an inhalation device comprises:

[0006] A mixer, wherein the mixer is provided with a mixing chamber;

[0007] An ultrasonic nebulizer, wherein the ultrasonic nebulizer is provided with a first atomization chamber and a first atomization channel communicating with the first atomization chamber, the first atomization channel communicating with the mixing chamber, and the first atomization chamber is used to contain a first liquid;

[0008] A heatable atomizer is provided with a second atomizing chamber and a second atomizing channel connected to the second atomizing chamber, the second atomizing channel is connected to the mixing chamber, the second atomizing chamber is used to hold a second liquid, and the second liquid is a solvent for the first liquid.

[0009] In one embodiment, the suction device further includes an exhauster, the exhauster includes an air inlet and an air outlet, and the air inlet is connected to the mixing chamber.

[0010] In one embodiment, the inhalation device further includes a first flow valve, which is provided on the ultrasonic nebulizer and communicates with the first atomization channel.

[0011] In one embodiment, the inhalation device further includes a second flow valve, which is provided on the heatable atomizer and communicates with the second atomization channel.

[0012] In one embodiment, the heatable atomizer is provided with a reflux channel, the reflux channel is spaced apart from the first atomizing channel, and the reflux channel is communicated with the mixing chamber and the second atomizing chamber.

[0013] In one embodiment, the inhalation device further comprises a sensor, wherein the sensor is disposed on the mixer and is in communication with the mixing chamber.

[0014] In one embodiment, the inhalation device further comprises a controller electrically connected to the sensor, the mixer, the ultrasonic nebulizer and the heatable nebulizer.

[0015] In one embodiment, the inhalation device further includes an air collecting hood, which is provided with an air collecting cavity and an air collecting inlet and an air collecting outlet connected to the air collecting cavity, the air collecting inlet is connected to the first atomization channel and the second atomization channel, and the air collecting outlet is connected to the mixing chamber.

[0016] In one embodiment, the inhalation device further comprises a mask, wherein the mask is in communication with the mixer.

[0017] In a second aspect, a drug delivery system comprises the inhalation device according to the first aspect.

[0018] The inhalation device comprises an ultrasonic nebulizer and a heatable nebulizer. The first atomization chamber of the ultrasonic nebulizer contains a first liquid (drug). The ultrasonic nebulizer uses high-frequency ultrasound to break the liquid into tiny droplets, reducing the first liquid's settling velocity. The second atomization chamber of the heatable nebulizer contains a second liquid (a solvent for the drug) and enables heated atomization. During drug delivery, the first and second liquids are separately atomized and then mixed in a mixing chamber of a mixer. This allows the solvent (second liquid) to fully contact the drug (first liquid) during the atomization and mixing process, promoting better dissolution of the drug in the solvent, thereby increasing the solubility of the drug droplets and, consequently, improving bioavailability. The ultrasonic nebulizer and heatable nebulizer are independently controlled to atomize the first and second liquids, respectively. During mixing in the mixing chamber, the adjustable droplet sizes of the two liquids make the resulting droplet size distribution more controllable. A more appropriate and controllable particle size distribution helps improve lung deposition efficiency. Because droplets of different sizes deposit at different locations and efficiencies in the lungs, droplets of the appropriate size are more likely to reach the target treatment area. Furthermore, the ultrasonic nebulizer and the heated nebulizer independently control the atomized volume of the first liquid (drug) and the second liquid (solvent), allowing real-time adjustment of the drug-solvent mixing ratio. This allows for more flexible adjustment of the drug-solvent ratio based on treatment needs, resulting in more precise drug delivery. The use of the ultrasonic nebulizer and the heated nebulizer further control the droplet size generated. This adjustment minimizes the generation of large droplets. Even if some relatively large droplets are present, they further refine or disperse after mixing with the atomized solvent (second liquid) droplets in the mixing chamber, reducing their proportion. This reduces the likelihood of large droplets remaining in the throat during inhalation, thereby improving drug delivery effectiveness and ensuring that more drug reaches the lung treatment area. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the conventional technology, the following briefly introduces the drawings required for use in the embodiments or the conventional technology descriptions. Obviously, the drawings described below are merely embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on the disclosed drawings without any creative work.

[0020] Figure 1 A schematic diagram of an inhalation device provided in an embodiment of the present application.

[0021] Explanation of the accompanying drawings: 100, inhalation device; 1, mixer; 11, mixing chamber; 2, ultrasonic nebulizer; 21, first atomizing channel; 22, first atomizing chamber; 3, heatable nebulizer; 31, second atomizing chamber; 32, second atomizing channel; 33, reflux channel; 4, exhauster; 41, air inlet; 42, air outlet; 51, first flow valve; 52, second flow valve; 6, sensor; 7, controller; 8, gas collecting hood; 81, gas collecting chamber; 82, gas collecting inlet; 83, gas collecting outlet; 9, mask. DETAILED DESCRIPTION

[0022] To make the above-mentioned objects, features, and advantages of the present application more clearly understood, the specific embodiments of the present application are described in detail below with reference to the accompanying drawings. The following description sets forth many specific details to facilitate a full understanding of the present application. However, the present application can be implemented in many other ways than those described herein, and those skilled in the art can make similar improvements without violating the scope of the present application. Therefore, the present application is not limited to the specific embodiments disclosed below.

[0023] Currently, pulmonary delivery of nanomedicines has attracted considerable attention for the treatment of lung diseases. Lung tissue, due to its unique physiological properties, including a large absorptive surface area, represents a promising drug delivery window. Compared to systemic drug delivery, nanoparticle inhalation offers several advantages for treating lung diseases, including improved pulmonary bioavailability. However, pulmonary delivery of nanomedicines for lung treatment still faces challenges, including low drug droplet solubility, uncontrollable particle size distribution, the inability to adjust the drug atomization and solvent mixing ratio in real time, and the tendency of large droplets to accumulate in the throat.

[0024] Based on the above problems, in the first aspect, the embodiments of the present application provide an inhalation device 100, which includes a mixer 1, an ultrasonic nebulizer 2 and a heatable nebulizer 3. In some embodiments, the mixer 1 is provided with a mixing chamber 11; the ultrasonic nebulizer 2 is provided with a first atomization chamber 22 and a first atomization channel 21 connected to the first atomization chamber 22, the first atomization channel 21 is connected to the mixing chamber 11, and the first atomization chamber 22 is used to hold a first liquid; the heatable nebulizer 3 is provided with a second atomization chamber 31 and a second atomization channel 32 connected to the second atomization chamber 31, the second atomization channel 32 is connected to the mixing chamber 11, and the second atomization chamber 31 is used to hold a second liquid, which is a solvent for the first liquid. In an optional embodiment, the first liquid is a medicament and the second liquid is a solvent for the medicament, such as water. The above-mentioned inhalation device 100 is provided with the first atomization chamber 22 of the ultrasonic nebulizer 2 containing the first liquid (drug), and the ultrasonic nebulizer 2 can break the first liquid into tiny droplets through high-frequency ultrasonic waves, significantly reducing the sedimentation rate of the first liquid. The second atomization chamber 31 of the heatable nebulizer 3 contains a second liquid (a solvent for the drug). Through nanoscale atomization and temperature control, the second liquid is heated and chemically transformed, achieving efficient, targeted delivery. During drug delivery, the first and second liquids are separately atomized and then mixed within the mixing chamber 11 of the mixer 1. This allows the solvent (second liquid) to fully contact the drug (first liquid) during the atomization and mixing process, promoting better dissolution of the drug in the solvent, thereby increasing the solubility of the drug droplets and, consequently, improving bioavailability. The ultrasonic nebulizer 2 and the heatable nebulizer 3 are independently regulated to atomize the first and second liquids, respectively. During mixing within the mixing chamber 11, the adjustable droplet size of the two liquids allows for a more controllable droplet size distribution. A more appropriate and controllable particle size distribution helps improve lung deposition efficiency, as droplets of different sizes deposit at different locations and efficiencies in the lungs. Droplets of the appropriate size are more likely to reach the target treatment area. At the same time, the ultrasonic nebulizer 2 and the heatable nebulizer 3 independently control the atomized amount of the first liquid (drug) and the second liquid (solvent), allowing real-time adjustment of the mixing ratio of the atomized drug and the solvent. This allows for more flexible adjustment of the drug-solvent ratio based on treatment needs, resulting in more precise drug administration. The provision of the ultrasonic nebulizer 2 and the heatable nebulizer 3 makes the droplet size formed more controllable. This adjustment minimizes the generation of large droplets of drug. Even if some relatively large droplets are present, they are further refined or dispersed after mixing with the droplets formed by atomization of the solvent (second liquid) in the mixing chamber 11, reducing the proportion of large droplets. This reduces the likelihood of large droplets of drug remaining in the throat during inhalation, thereby improving the effectiveness of drug delivery and enabling more drug to reach the lung treatment site.

[0025] The ultrasonic nebulizer 2 and the heatable nebulizer 3 are each equipped with a separate atomization channel connected to the mixer 1. This ensures independent atomization, precisely controls the mixing ratio, prevents cross-contamination, and improves mixing uniformity. When the two nebulizers atomize the first liquid (drug solution) and the second liquid (drug solution solvent), respectively, the independent atomization channels ensure that they complete the atomization process within their respective channels without interference. The independent atomization channels facilitate independent control of the flow rates of the first and second liquids, allowing precise control of the amounts of drug and solvent entering the mixer 1 and, therefore, precisely adjusting the drug-solvent mixing ratio. Different drug concentrations may be required for treating different lung diseases or for different patients. This ability to precisely control the mixing ratio can meet diverse treatment needs. Since the two liquids enter the mixer 1 through separate channels, the possibility of cross-contamination and contamination before atomization is reduced. If the two liquids are mixed prematurely, chemical reactions or physical changes may occur, affecting the stability and effectiveness of the drugs. Independent atomization channels ensure that the properties of the drug and solvent remain stable before entering the mixer 1. The independent atomization channels allow the drug and solvent to enter the mixer 1 in relatively independent atomized states. In mixer 1, the two independently atomized droplets can more fully collide and merge with each other, achieving more uniform mixing. Compared to a single channel that directly delivers pre-mixed liquid to mixer 1, this method of independent atomization followed by mixing allows for more complete contact between the drug and solvent at the microscopic level, improving mixing uniformity. This in turn ensures that the resulting drug droplets are more consistent in composition and concentration, enhancing the stability of the therapeutic effect.

[0026] It should be noted that both the ultrasonic nebulizer 2 and the heatable nebulizer 3 are commercially available. They can be mesh nebulizers, vibrating mesh nebulizers, or the like. A mesh nebulizer squeezes liquid medication through tiny mesh holes to form droplets. A vibrating mesh nebulizer uses a vibrating mesh plate to break up the liquid into tiny droplets. The specific structures of the ultrasonic nebulizer 2 and the heatable nebulizer 3 are not described in detail here.

[0027] In some embodiments, the inhalation device 100 further includes a first flow valve 51, which is provided on the ultrasonic nebulizer 2 and communicates with the first atomization channel 21. The first flow valve 51 can accurately control the flow rate of the drug liquid entering the first atomization channel 21 from the ultrasonic nebulizer 2, thereby adjusting the atomized amount of the drug liquid.

[0028] In some embodiments, the inhalation device 100 further includes a second flow valve 52, which is disposed on the heated atomizer 3 and communicates with the second atomization channel 32. The second flow valve 52 can precisely control the liquid flow of the solvent entering the second atomization channel 32 from the heated atomizer 3, thereby adjusting the atomized amount of the solvent.

[0029] In some embodiments, the inhalation device 100 further includes an air collecting hood 8, which is provided with an air collecting cavity 81 and an air collecting inlet 82 and an air collecting outlet 83 connected to the air collecting cavity 81, wherein the air collecting inlet 82 is connected to the first atomizing channel 21 and the second atomizing channel 32, and the air collecting outlet 83 is connected to the mixing chamber 11. The air collecting inlet 82 of the air collecting hood 8 is connected to the first atomizing channel 21 and the second atomizing channel 32, and can effectively converge the atomized gas from different atomizing channels into the air collecting cavity 81. This can prevent the atomized gas from dispersing and escaping within the device, improve the collection efficiency of the atomized gas, ensure that there is enough atomized gas to enter the mixing chamber 11 for mixing and transportation, and provide a stable source of drug droplets for the patient. The air collecting cavity 81 provides a mixing space for the atomized gas from different channels. In the air collecting cavity 81, the atomized gas has the opportunity to undergo preliminary mixing, so that the drug droplets from different sources can be evenly mixed with each other. This helps to pre-mix the atomized gas before entering the mixing chamber 11, thereby improving the uniformity of the atomized gas in the final mixing chamber 11, thereby making the concentration of the drug droplets inhaled by the patient more stable and ensuring the consistency of the treatment effect. The gas collecting hood 8 can play a role in buffering the gas pressure. During the atomization process, the gas pressure in the atomization channel may fluctuate. The gas collecting chamber 81 can accommodate a certain amount of gas, which plays a buffering role against pressure fluctuations. When the pressure rises, the gas collecting chamber 81 can temporarily store excess gas to avoid damage to subsequent components due to excessive pressure; when the pressure drops, the gas in the gas collecting chamber 81 can be replenished to maintain the stability of the gas flow and ensure a smooth inhalation process for the patient.

[0030] In an optional embodiment, the mixer 1 is a cyclone mixer 1. The cyclone mixer 1 can also be purchased commercially. When the cyclone mixer 1 is working, a high-speed rotating airflow field will be formed inside. After the droplets produced by the ultrasonic atomizer 2 and the heatable atomizer 3 respectively enter the cyclone mixer 1, under the action of centrifugal force, the high-speed rotating airflow causes the droplets to fully collide and disperse in a three-dimensional spiral motion, so that the droplets are further broken up and broken into smaller droplets. Droplets of different densities or particle sizes usually tend to stratify under the action of gravity, with droplets of high density sinking and droplets of low density floating. In the cyclone mixer 1, the high-speed rotating airflow generates a strong centrifugal force. After the droplets enter the mixer 1, they will perform a three-dimensional spiral motion. In this process, the centrifugal force is much greater than the gravity, so that the droplets of different densities and particle sizes are no longer stratified according to the direction of gravity, but are all drawn into the spiral motion trajectory. Large, heavier droplets do not sink rapidly due to gravity. Instead, they rotate continuously within the mixer 1 along with the lighter, smaller droplets, thus preventing stratification. The three-dimensional spiral motion provides a complex and continuous path for the droplets. During their motion, the droplets constantly change direction and speed, significantly increasing the probability of collisions. When droplets collide, the impact force generated by the collision breaks up any agglomerated droplets. Furthermore, because each droplet has a unique trajectory, they collide at different locations and angles, further ensuring effective droplet dispersion. The high-speed, rotating airflow creates a velocity gradient within the mixer 1, resulting in different airflow velocities at different locations. As the droplets move with the airflow, the varying airflow velocities at their respective locations subject them to shear forces, which can separate the agglomerated droplets. For example, for large agglomerates of multiple small droplets, shear forces pull the agglomerates in different directions, gradually breaking them up into smaller droplets. This shear force not only breaks up agglomerated droplets but also further fragments larger droplets. Under the continuous action of shear force, larger droplets will be gradually refined, making the particle size of the droplets in the entire mixture gradually uniform. After being subjected to the action of shear force, droplets of different densities and particle sizes can be adjusted to a relatively consistent size range, thereby ensuring the uniformity of the particle size distribution of the mixture. The airflow inside the cyclone mixer 1 forms a circular flow pattern, and the droplets will continue to circulate in the mixer 1. This means that each droplet has multiple opportunities to participate in mixing and collision. Even if it is not completely broken up or mixed evenly in a certain collision, it still has the opportunity to collide and mix with other droplets again in the subsequent circulation process, thereby continuously improving the uniformity of the mixing. During the continuous mixing process, a dynamic equilibrium state will gradually be reached in the mixer 1. Newly entered droplets will quickly integrate into the existing mixing system, and the already mixed parts will continue to maintain a uniform state. This dynamic balance can effectively maintain the uniformity of the particle size distribution of the mixture and avoid local unevenness.

[0031] In some embodiments, the heatable nebulizer 3 is provided with a reflux channel 33, which is spaced apart from the first atomizing channel 21, and the reflux channel 33 is connected to the mixing chamber 11 and the second atomizing chamber 31. Some of the drug droplets that are not inhaled in time or are excess in the mixing chamber 11 can return to the second atomizing chamber 31 through the reflux channel 33. These droplets can be mixed with newly generated droplets to participate in the atomization process again, thereby avoiding the waste of the drug and improving the utilization rate of the drug. At the same time, droplets with larger particle sizes can be thrown out by the mixer 1 into the reflux channel 33 and mixed with the liquid medicine solvent of the heatable nebulizer 3, which is beneficial to controlling the particle size distribution of the droplets and improving the solubility of the drug droplets.

[0032] In some embodiments, the inhalation device 100 further includes a mask 9, which is in communication with the mixer 1. The mask 9 is configured to cover the user's mouth and nose, making it easier for the user to inhale the medicine.

[0033] In some embodiments, the inhalation device 100 also includes an aspirator 4, which includes an air inlet 41 and an air outlet 42, and the air inlet 41 is connected to the mixing chamber 11. The air outlet 42 is used for the user to inhale. The airflow generated by the aspirator 4 can transport the drug droplets in the mixing chamber 11 to the user's mouth at a suitable speed and force, avoiding excessive dispersion or accumulation of the droplets, so that the patient can feel a stable and continuous droplet flow, thereby making it easier to control the breathing rhythm, reduce the occurrence of discomfort such as choking or difficulty breathing, and improve the comfort and smoothness of the inhalation process. Since the aspirator 4 continuously extracts the droplets in the mixing chamber 11 and guides them to the user, the residual drug droplets in the mixing chamber 11 can be effectively reduced. Compared with the case where there is no aspirator 4, the possibility of the drug adhering to the wall of the mixing chamber 11 or depositing in the corner is reduced, which not only improves the utilization rate of the drug.

[0034] In an optional embodiment, the air outlet 42 of the air extractor 4 is communicated with the mask 9. The air extractor 4 extracts the mist droplets to the mask 9 for the user to inhale.

[0035] In an optional embodiment, the air outlet 42 of the exhauster 4 is connected to the mask 9 through a slender micro-nozzle, and the slender micro-nozzle can enable targeted and precise delivery of the atomized liquid.

[0036] In some embodiments, the inhalation device 100 further includes a sensor 6, which is disposed on the mixer 1 and communicates with the mixing chamber 11. The sensor 6 can monitor the particle size of the droplets in the mixer 1 in real time and can also detect the concentration of the droplets in the mixed gas. The sensor 6 can be a particle size analyzer, an optical concentration sensor 6, or a capacitive concentration sensor 6.

[0037] In some embodiments, the inhalation device 100 further includes a controller 7, which is electrically connected to the sensor 6, the mixer 1, the ultrasonic nebulizer 2, and the heatable nebulizer 3. The sensor 6 can transmit the detected droplet data to the controller 7, and the controller 7 controls the ultrasonic nebulizer 2 and the heatable nebulizer 3.

[0038] Furthermore, the controller 7 is electrically connected to the first flow valve 51, the second flow valve 52, and the aspirator 4, and can simultaneously control the first flow valve 51, the second flow valve 52, and the aspirator 4, forming a closed-loop coordinated control system, which can adjust the atomized particle size in real time according to the needs of different patients, ultimately ensuring more effective drug delivery to the patient's lungs.

[0039] In a second aspect, an embodiment of the present application further provides a drug delivery system, which includes the inhalation device 100 of the first aspect, and the drug delivery system also has all the technical effects of the inhalation device 100.

[0040] In summary, the inhalation device 100 provided in the embodiment of the present application achieves coordinated control by providing an ultrasonic nebulizer 2 and a heatable nebulizer 3, achieving precise droplet concentration adaptation. The mixed gas is provided to achieve high homogeneity, resolve droplet stratification, ensure uniform droplet size distribution, and improve drug delivery efficiency. By providing a sensor 6 and a controller 7, droplet parameters are detected and dynamically adjusted in real time, enabling user-adaptive real-time adjustment of droplet size to meet differentiated treatment needs.

[0041] In the description of this application, it should be understood that if the terms "center", "longitudinal", "lateral", "length", "width", "thickness", "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom", "inside", "outside", "clockwise", "counterclockwise", "axial", "radial", "circumferential", etc. appear, the orientation or position relationship indicated by these terms is based on the orientation or position relationship shown in the accompanying drawings, which is only for the convenience of describing this application and simplifying the description, and does not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as a limitation on this application.

[0042] In addition, if the terms "first" or "second" appear, these terms are used for descriptive purposes only and should not be understood to indicate or imply relative importance or implicitly specify the number of technical features indicated. Therefore, a feature specified as "first" or "second" may explicitly or implicitly include at least one of such features. In the description of this application, if the term "plurality" appears, "plurality" means at least two, for example, two, three, etc., unless otherwise specifically defined.

[0043] In this application, unless otherwise specified or limited, the terms "mounted," "connected," "connected," "fixed," etc., should be interpreted broadly. For example, these terms may refer to fixed connections, removable connections, or integration; mechanical connections or electrical connections; direct connections or indirect connections through an intermediary; and internal communication between two components or interaction between two components, unless otherwise specified. Those skilled in the art will understand the specific meanings of these terms in this application based on the specific circumstances.

[0044] In this application, unless otherwise expressly specified or limited, if a first feature is described as being "above" or "below" a second feature, or similar descriptions, this may mean that the first and second features are in direct contact, or that the first and second features are in indirect contact through an intermediate medium. Furthermore, when a first feature is described as being "above," "above," or "above" a second feature, it may mean that the first feature is directly above or diagonally above the second feature, or simply means that the first feature is at a higher level than the second feature. When a first feature is described as being "below," "below," or "below" a second feature, it may mean that the first feature is directly below or diagonally below the second feature, or simply means that the first feature is at a lower level than the second feature.

[0045] It should be noted that if an element is referred to as being "fixed to" or "disposed on" another element, it may be directly on the other element or there may be an intermediate element. If an element is considered to be "connected to" another element, it may be directly connected to the other element or there may be an intermediate element. If any, the terms "vertical", "horizontal", "upper", "lower", "left", "right" and similar expressions used in this application are for illustrative purposes only and do not represent the only embodiment.

[0046] The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the technical features in the above-mentioned embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0047] The above-described embodiments merely represent several implementation methods of the present application. While the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the patent application. It should be noted that a person of ordinary skill in the art may make various modifications and improvements without departing from the spirit of the present application, and these modifications and improvements fall within the scope of protection of the present application. Therefore, the scope of protection of the present patent application shall be determined by the appended claims.

Claims

1. An inhalation device, characterized in that include: A mixer, wherein the mixer is provided with a mixing chamber; An ultrasonic nebulizer, wherein the ultrasonic nebulizer is provided with a first atomization chamber and a first atomization channel communicating with the first atomization chamber, the first atomization channel communicating with the mixing chamber, and the first atomization chamber is used to contain a first liquid; A heatable atomizer is provided with a second atomizing chamber and a second atomizing channel connected to the second atomizing chamber, the second atomizing channel is connected to the mixing chamber, the second atomizing chamber is used to hold a second liquid, and the second liquid is a solvent for the first liquid.

2. The inhalation device according to claim 1, characterized in that The suction device further comprises an air extractor, wherein the air extractor comprises an air inlet and an air outlet, and the air inlet is communicated with the mixing chamber.

3. The inhalation device according to claim 1, characterized in that The inhalation device further includes a first flow valve, which is provided on the ultrasonic nebulizer and communicates with the first atomization channel.

4. The inhalation device according to claim 1, wherein The inhalation device further comprises a second flow valve, which is provided on the heatable atomizer and communicates with the second atomization channel.

5. The inhalation device according to claim 1, characterized in that The heatable atomizer is provided with a reflux channel, the reflux channel is spaced apart from the first atomizing channel, and the reflux channel is communicated with the mixing chamber and the second atomizing chamber.

6. The inhalation device according to claim 1, characterized in that The inhalation device further comprises a sensor, which is arranged on the mixer and communicates with the mixing chamber.

7. The inhalation device according to claim 6, characterized in that The inhalation device further includes a controller electrically connected to the sensor, the mixer, the ultrasonic nebulizer, and the heatable nebulizer.

8. The inhalation device according to any one of claims 1 to 7, characterized in that The inhalation device also includes an air collecting hood, which is provided with an air collecting cavity and an air collecting inlet and an air collecting outlet connected to the air collecting cavity. The air collecting inlet is connected to the first atomization channel and the second atomization channel, and the air collecting outlet is connected to the mixing chamber.

9. The inhalation device according to any one of claims 1 to 7, characterized in that The inhalation device further includes a mask in communication with the mixer.

10. A drug delivery system, characterized in that The drug delivery system comprises the inhalation device according to any one of claims 1 to 9.

Images